Vazkepa: The Secret Weapon Against Cholesterol
Reducing LDL cholesterol, commonly known as "bad cholesterol," is essential to lowering the risk of cardiovascular complications and mortality. This was emphasized by Dr. Alberto Cordero Fort, a cardiologist at IMED Hospital in Elche, during an interview with Europa Press Infosalus.
Dr. Cordero highlighted that, in addition to maintaining a healthy diet, exercising, and avoiding smoking, it is crucial to strictly follow prescribed treatments, especially after a heart attack. According to him, these measures have significantly reduced mortality rates from cardiovascular events.
Among the most notable advancements in cholesterol management and cardiovascular prevention is 'Vazkepa.' This drug, used in patients with high triglyceride levels and heart disease or diabetes, has been shown to reduce mortality and associated complications by 25%.
'Vazkepa' not only lowers LDL cholesterol levels but also tackles inflammation, a key factor in cardiovascular risk. With more than 14,000 patients discharged after a heart attack in Spain, the medication emerges as an innovative solution for those at higher risk.
The impact of 'Vazkepa' underscores the importance of raising awareness about treatment adherence and its role in combating cardiovascular diseases, saving lives, and offering hope to thousands of patients.
